Great Lakes Advisors LLC Grows Holdings in Stryker Co. (NYSE:SYK)

Great Lakes Advisors LLC boosted its position in shares of Stryker Co. (NYSE:SYK) by 2.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 21,070 shares of the medical technology company’s stock after acquiring an additional 532 shares during the period. Great Lakes Advisors LLC’s holdings in Stryker were worth $7,586,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the company. EverSource Wealth Advisors LLC lifted its stake in shares of Stryker by 19.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,469 shares of the medical technology company’s stock valued at $529,000 after buying an additional 243 shares in the last quarter. Sequoia Financial Advisors LLC lifted its position in shares of Stryker by 7.5% in the fourth quarter. Sequoia Financial Advisors LLC now owns 12,074 shares of the medical technology company’s stock valued at $4,347,000 after acquiring an additional 838 shares in the last quarter. HighTower Advisors LLC boosted its stake in shares of Stryker by 3.0% in the fourth quarter. HighTower Advisors LLC now owns 432,332 shares of the medical technology company’s stock worth $155,661,000 after acquiring an additional 12,479 shares during the period. Moors & Cabot Inc. boosted its stake in shares of Stryker by 0.4% in the fourth quarter. Moors & Cabot Inc. now owns 10,686 shares of the medical technology company’s stock worth $3,847,000 after acquiring an additional 43 shares during the period. Finally, Natural Investments LLC purchased a new stake in shares of Stryker during the fourth quarter worth about $1,528,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Activity

In other news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on SYK. Argus set a $450.00 price target on Stryker in a report on Monday, February 3rd. Canaccord Genuity Group raised their target price on shares of Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Stifel Nicolaus boosted their price target on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Wells Fargo & Company raised their price objective on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Finally, JPMorgan Chase & Co. lifted their target price on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $421.90.

Stryker Stock Performance

Shares of NYSE:SYK opened at $363.79 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a market capitalization of $138.81 billion, a price-to-earnings ratio of 46.88, a PEG ratio of 2.93 and a beta of 0.95. The firm’s 50-day moving average is $382.87 and its 200 day moving average is $373.26.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the business earned $3.46 EPS. Research analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. Stryker’s dividend payout ratio (DPR) is 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.